Researcher and Angel Investor in Dallas, Texas
Dr. Beth Rosellini is an accomplished medtech industry professional with experience ranging from early traction in R&D to delivery of direct patient care. Beth serves as an independent MedTech Researcher & Angel Investor, where she dedicates her time to researching projects and investing in medtech companies.
Previously, Beth Rosellini served as the Vice President of Clinical Affairs at Nexeon MedSystems, Inc., an operational investment company that specializes in leveraging substantial non-dilutive funding to de-risk clinical programs to develop innovative, physician-driven, benchtop science into commercialized, precision medicine therapies via tax-optimized vehicles. In addition to an ongoing pipeline of intellectual property under development, Nexeon also maintains a portfolio of cutting-edge life sciences companies that have programs in implantable neuromodulation, interventional cardiology, telemedicine, and virtual and augmented reality usage in the medical field.
Beth Rosellini began her role at Nexeon after assets from Rosellini Scientific, a medtech incubator, were contributed to the Company. At Rosellini Scientific, she served as General Partner as well as a member of executive teams on the programs initiated there. Dr. Rosellini used her expertise in multi-disciplinary, systemic health management systems in optimizing next-generation, point-of- care medicine with “smart” devices with an overall aim to help patients get access to better care faster.
Originally from Texas, Beth Rosellini holds a Doctor of Dental Surgery from the Texas A&M University Baylor College of Dentistry. She entered the field of Medical Technology through her role as General Partner with Rosellini Scientific, where she worked closely with experts in the translational medicine and med tech startup world.
In addition to her position with Nuviant, Beth Rossellini serves as the Chief Clinical Officer for TeleMend Medical, Inc., where she works to integrate healthcare technology, remote patient therapy, and advanced care delivery into the medical field. In this capacity, she consistently interacts with patients who find themselves desperate for solutions, whic